crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 913175

Časopis

Autori: Hauser, Goran; Blažević, Ivana; Salkić, Nermin; Poropat, Goran; Giljača, Vanja; Bulić, Zlatko; Štimac, Davor
Naslov: Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
( Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial. )
Izvornik: Surgical endoscopy (0930-2794) 31 (2017); 602-610
Vrsta rada: članak
Ključne riječi: ERCP, Post ERCP pancreatitis
( ERCP, Post ERCP pancreatitis )
Sažetak:
Background and Aims: We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Methods: We prospectively enrolled patients who underwent ERCP. In a doubleblinded randomized controlled trial, patients received a suppository containing diclofenac sodium rectally (100 mg) and placebo intravenously (group A) or ceftazidime intravenously (1 g) and placebo rectally (group B) immediately before the procedure. The serum and urine amylase levels were recorded and the patients were clinically evaluated after ERCP. Results: Of the 272 patients enrolled (group A: 129 ; group B: 143), 32 developed pancreatitis (group A: 11 [8.5%] ; group B: 21 [14.7%] ; P = 0.17 ; relative risk = 1.72 ; 95% confidence interval [CI] = 0.86-3.43). The severity of the pancreatitis or complications did not significantly differ between the groups. A serum amylase level of ≥ 560 U/L and urine amylase level of ≥ 1150 U/L indicated a positive likelihood ratio for post-ERCP pancreatitis of ≥ 10. Moreover, the threshold visual analog scale score of ≤ 5 for abdominal pain after ERCP had excellent diagnostic potential for predicting the presence or absence of post-ERCP pancreatitis. Conclusions: The PEP incidence did not differ between the ceftazidime and diclofenac sodium groups. In patients with nonsteroidal anti-inflammatory drug contraindications, antibiotics can be considered a safe alternative to diclofenac sodium for PEP prevention. Moreover, the visual analog scale for abdominal pain has excellent diagnostic value for predicting PEP. Clinical trials.gov number, NCT 01784445.
Izvorni jezik: eng
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
MEDLINE
Scopus
SCI-EXP, SSCI i/ili A&HCI
Science Citation Index Expanded (SCI-EXP) (sastavni dio Web of Science Core Collectiona)
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
URL Internet adrese: https://link.springer.com/article/10.1007%2Fs00464-016-5004-9
Broj citata:
Altmetric:
DOI: 10.1007/s00464-016-5004-9
URL cjelovitog teksta:
Google Scholar: Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Upisao u CROSBI: Goran Hauser (goran.hauser@uniri.hr), 17. Pro. 2017. u 17:08 sati



  Verzija za printanje   za tiskati


upomoc
foot_4